Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Acceleron Pharma Inc. (XLRN)

178.75   0 (0%) 12-31 19:00
Open: 179.85 Pre. Close: 178.75
High: 179.85 Low: 177.2
Volume: 7,884,284 Market Cap: 0(M)

Technical analysis

as of: 2022-01-21 4:31:52 PM
Short-term rate:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Mid-term rate:       
Target: Six months: 210.06     One year: 245.35
Support: Support1: 178.21    Support2: 177.19
Resistance: Resistance1: 179.85    Resistance2: 210.06
Pivot: 178.75
Moving Average: MA(5): 178.75     MA(20): 178.75
MA(100): 170.29     MA(250): 144.27
MACD: MACD(12,26): 0.2     Signal(9): 0.28
Stochastic oscillator: %K(14,3): 58.49     %D(3): 58.49
RSI: RSI(14): 71.18
52-week: High: 189.99  Low: 111.75
Average Vol(K): 3-Month: 0 (K)  10-Days: 0 (K)

Price, moving averages and Bollinger Bands

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: - -
Low: - -
Close: - -

Company Description

Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Headline News

Wed, 30 Aug 2023
New nod brings Reblozyl into first-line treatment setting - The Pharma Letter

Wed, 05 Jul 2023
Lehigh Names New Trustees - Lehigh University

Mon, 22 Nov 2021
Merck Closes Deal for Acceleron Pharma, Biggest Biotech Merger of the Year - Barron's

Mon, 22 Nov 2021
Merck Completes Acquisition of Acceleron Pharma Inc. - Business Wire

Tue, 09 Nov 2021
Avoro Capital Releases Presentation Detailing Why Acceleron ... - Business Wire

Thu, 04 Nov 2021
Acceleron Reports Third Quarter 2021 Financial Results - Business Wire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 61 (M)
Shares Float 50 (M)
% Held by Insiders 11.7 (%)
% Held by Institutions 91.4 (%)
Shares Short 1,680 (K)
Shares Short P.Month 1,980 (K)

Stock Financials

EPS -3.72
EPS Est Next Qtl -0.64
EPS Est This Year -2.7
EPS Est Next Year -2.28
Book Value (p.s.) 12.56
Profit Margin (%) -221.14
Operating Margin (%) -221.59
Return on Assets (ttm) -21.3
Return on Equity (ttm) -37.76
Qtrly Rev. Growth -29.71
Gross Profit (p.s.) -1.34
Sales Per Share 1.65
EBITDA (p.s.) -3.61
Qtrly Earnings Growth 0
Operating Cash Flow -193 (M)
Levered Free Cash Flow -108 (M)

Stock Valuations

PE Ratio -48.19
PEG Ratio 0
Price to Book value 14.23
Price to Sales 108.04
Price to Cash Flow -0.01

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.